Mighty, I have seen and read more midkine papers with positive research to occupy an entire to row of text books at the New York City library.
Without a commercial deal behind any of the research we all know it means sweet FA for shareholders.
The question needs to be asked why hasn’t this happened?
- does big pharma want a bigger slice of the cake than Cellmid is willing to cut?
- maybe the cake looks enticing but no one is willining to try it?
- or other possibilities ?
Either way midkine needs to commercialised with real money instead of being talked about like the amazing holy grail that slipped away.
- Forums
- ASX - By Stock
- AN1
- Research: Midkine Controls Arteriogenesis by Regulating VEGFA Bioavailability and NOS Expression
Research: Midkine Controls Arteriogenesis by Regulating VEGFA Bioavailability and NOS Expression, page-3
-
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AN1 (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.690M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
AN1 (ASX) Chart |
Day chart unavailable